StockNews.AI
SNOA
StockNews.AI
162 days

Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)

1. SNOA registered five products with the UK's MHRA, enhancing market access. 2. This includes important wound care solutions, expanding their product portfolio.

2m saved
Insight
Article

FAQ

Why Bullish?

Registration with MHRA opens new market opportunities, as seen in past FDA approvals boosting stock prices.

How important is it?

Market entry in the UK can significantly increase revenue potential and credibility.

Why Short Term?

Immediate sales can be expected in the UK following registration.

Related Companies

SNOA
BOULDER, CO / ACCESS Newswire / March 10, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the registration of its manufacturing facility and five of its products with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. The newly registered products include Sonoma's hypochlorous acid-based wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant.

Related News